BridgeBio Pharma’s BBP-812 Trial Shows Promise for Canavan Disease Amidst Focus on Acoramidis
Leerink Partners analyst Mani Foroohar has maintained their bullish stance on BBIO stock, giving a Buy rating today. Mani Foroohar’s ...
Optimistic Buy Rating for BridgeBio Pharma’s BBP-812: Promising Phase 1/2 Results in Canavan Disease Therapy
Mizuho Securities analyst Salim Syed has maintained their bullish stance on BBIO stock, giving a Buy rating today. Salim Syed’s rating ...
LQWD Technologies acquires 16 more bitcoin
LQWD Technologies (TSXV:LQWD) reveals it has added an additional 16 bitcoin to its portfolio, bringing its total bitcoin held ...
ATEX notches C$55 million investment from Agnico Eagle Mines
ATEX Resources (TSXV:ATX) reveals it has received a strategic investment of C$55 million from Agnico Eagle Mines (TSX:AEM) ...